A retrospective study in 51 patients with SLE-related PAH reported 3-year and 5-year survival rates of 89.4% and 83.9%, respectively, while the presence of anti-U1-RNP antibodies was associated with an improved prognosis [62]. This evidence concerns the gene RNPC3 and systemic lupus erythematosus.